Low Hemoglobin Linked to 66% Higher Dementia Risk in 9-Year Study

Dementia prevention is one of the most pressing challenges in longevity medicine, and a new study adds a surprising and potentially actionable factor to the equation: hemoglobin levels. Research published in JAMA Network Open suggests that anemia — a condition affecting roughly 25% of the global population — may meaningfully accelerate dementia risk, especially when combined with established Alzheimer's disease biomarkers.

The study followed 2,300 older Swedish adults without dementia for a mean of nine years. Those with anemia had a 66% higher risk of developing dementia (HR 1.66). Anemia was also cross-sectionally linked to elevated levels of three key Alzheimer's blood biomarkers: phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) — all markers of neurodegeneration and brain inflammation.

The most alarming finding was the compounding effect. When anemia coexisted with high NfL levels, dementia hazard ratio reached 3.64 — more than triple the baseline risk. This suggests anemia does not merely correlate with dementia but may actively worsen the brain's ability to withstand neurodegeneration, creating a dangerous biological synergy.

Researchers from the Karolinska Institute propose that low hemoglobin may reduce oxygen delivery to the brain, impairing its resilience to Alzheimer's pathology already underway. An accompanying editorial from Erasmus MC highlighted that anemia is most prevalent in regions projected to see the steepest dementia increases globally, amplifying the public health stakes.

For health-conscious individuals, this research points to hemoglobin monitoring as a potentially underutilized tool in dementia risk stratification. Treating anemia — whether through iron, B12, diet, or addressing underlying causes — could represent a modifiable lever in brain health. Causality has not been established, and mechanistic trials are needed before clinical protocols change.